Search Results - "FRENCH, Ruth R"

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies by White, Ann L., Chan, H.T. Claude, French, Ruth R., Willoughby, Jane, Mockridge, C. Ian, Roghanian, Ali, Penfold, Christine A., Booth, Steven G., Dodhy, Ali, Polak, Marta E., Potter, Elizabeth A., Ardern-Jones, Michael R., Verbeek, J. Sjef, Johnson, Peter W.M., Al-Shamkhani, Aymen, Cragg, Mark S., Beers, Stephen A., Glennie, Martin J.

“…Monoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer treatment but require optimization for maximum clinical impact. Here,…”
Get full text

Mechanisms of killing by anti-CD20 monoclonal antibodies by Glennie, Martin J., French, Ruth R., Cragg, Mark S., Taylor, Ronald P.

“…CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but not stem or plasma cells. It is an ideal target for monoclonal…”
Get full text

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy by Lim, Sean H., Vaughan, Andrew T., Ashton-Key, Margaret, Williams, Emily L., Dixon, Sandra V., Chan, H. T. Claude, Beers, Stephen A., French, Ruth R., Cox, Kerry L., Davies, Andrew J., Potter, Kathleen N., Mockridge, C. Ian, Oscier, David G., Johnson, Peter W.M., Cragg, Mark S., Glennie, Martin J.

“…The anti-CD20 mAb rituximab is central to the treatment of B-cell malignancies, but resistance remains a significant problem. We recently reported that…”
Get full text

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection by Beers, Stephen A., French, Ruth R., Chan, H.T. Claude, Lim, Sean H., Jarrett, Timothy C., Vidal, Regina Mora, Wijayaweera, Sahan S., Dixon, Sandra V., Kim, Hyungjin, Cox, Kerry L., Kerr, Jonathan P., Johnston, David A., Johnson, Peter W.M., Verbeek, J. Sjef, Glennie, Martin J., Cragg, Mark S.

“…Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this…”
Get full text

Anti-CD20 monoclonal antibodies: historical and future perspectives by LIM, Sean H, BEERS, Stephen A, FRENCH, Ruth R, JOHNSON, Peter W. M, GLENNIE, Martin J, CRAGG, Mark S

“…Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal,…”
Get full text

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies by Beers, Stephen A, Chan, Claude H.T, French, Ruth R, Cragg, Mark S, Glennie, Martin J

“…The last decade has seen the monoclonal antibody (mAb), rituximab, transform clinical management of many non-Hodgkin lymphomas and more recently provide new…”
Get full text

The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 by Teeling, Jessica L, Mackus, Wendy J. M, Wiegman, Luus J. J. M, van den Brakel, Jeroen H. N, Beers, Stephen A, French, Ruth R, van Meerten, Tom, Ebeling, Saskia, Vink, Tom, Slootstra, Jerry W, Parren, Paul W. H. I, Glennie, Martin J, van de Winkel, Jan G. J

“…We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly efficient in their ability to recruit C1q to the surface of…”
Get full text

Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling by Walshe, Claire A., Beers, Stephen A., French, Ruth R., Chan, Claude H.T., Johnson, Peter W., Packham, Graham K., Glennie, Martin J., Cragg, Mark S.

“…The anti-CD20 monoclonal antibody (mAb) rituximab is now routinely used for the treatment of non-Hodgkins lymphoma and is being examined in a wide range of…”
Get full text

CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses by Castro, Fernanda V.V, Tutt, Alison L, White, Ann L, Teeling, Jessica L, James, Sonya, French, Ruth R, Glennie, Martin J

“…The magnitude and quality of T cell responses generated when Ag is targeted to receptors on DC is influenced by both the specific receptor targeted and its…”
Get full text

TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity by Yu, Xiaojie, James, Sonya, Felce, James H., Kellermayer, Blanka, Johnston, David A., Chan, H. T. Claude, Penfold, Christine A., Kim, Jinny, Inzhelevskaya, Tatyana, Mockridge, C. Ian, Watanabe, Yasunori, Crispin, Max, French, Ruth R., Duriez, Patrick J., Douglas, Leon R., Glennie, Martin J., Cragg, Mark S.

“…Monoclonal antibodies (mAb) and natural ligands targeting costimulatory tumor necrosis factor receptors (TNFR) exhibit a wide range of agonistic activities and…”
Get full text

On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation by Sopp, Joshua M., Peters, Shirley J., Rowley, Tania F., Oldham, Robert J., James, Sonya, Mockridge, Ian, French, Ruth R., Turner, Alison, Beers, Stephen A., Humphreys, David P., Cragg, Mark S.

“…The majority of depleting monoclonal antibody (mAb) drugs elicit responses via Fc-FcγR and Fc-C1q interactions. Optimal C1q interaction is achieved through…”
Get full text

Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity by Yu, Xiaojie, Chan, H.T. Claude, Fisher, Hayden, Penfold, Christine A., Kim, Jinny, Inzhelevskaya, Tatyana, Mockridge, C. Ian, French, Ruth R., Duriez, Patrick J., Douglas, Leon R., English, Vikki, Verbeek, J. Sjef, White, Ann L., Tews, Ivo, Glennie, Martin J., Cragg, Mark S.

“…Anti-CD40 monoclonal antibodies (mAbs) comprise agonists and antagonists, which display promising therapeutic activities in cancer and autoimmunity,…”
Get full text

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies by Yu, Xiaojie, Chan, H.T. Claude, Orr, Christian M., Dadas, Osman, Booth, Steven G., Dahal, Lekh N., Penfold, Christine A., O'Brien, Lyn, Mockridge, C. Ian, French, Ruth R., Duriez, Patrick, Douglas, Leon R., Pearson, Arwen R., Cragg, Mark S., Tews, Ivo, Glennie, Martin J., White, Ann L.

“…Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function hold promise as therapeutics for cancer and autoimmunity. Rules governing…”
Get full text

OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential by Lai, Chester, August, Suzannah, Albibas, Amel, Behar, Ramnik, Cho, Shin-Young, Polak, Marta E, Theaker, Jeffrey, MacLeod, Amanda S, French, Ruth R, Glennie, Martin J, Al-Shamkhani, Aymen, Healy, Eugene

“…Cutaneous squamous cell carcinoma (cSCC) is the most common human cancer with metastatic potential. Despite T cells accumulating around cSCCs, these tumors…”
Get full text

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody by White, Ann L, Chan, H T Claude, Roghanian, Ali, French, Ruth R, Mockridge, C Ian, Tutt, Alison L, Dixon, Sandra V, Ajona, Daniel, Verbeek, J Sjef, Al-Shamkhani, Aymen, Cragg, Mark S, Beers, Stephen A, Glennie, Martin J

“…A high activatory/inhibitory FcγR binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and…”
Get full text

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies by Tipton, Thomas R.W., Roghanian, Ali, Oldham, Robert J., Carter, Matthew J., Cox, Kerry L., Mockridge, C. Ian, French, Ruth R., Dahal, Lekh N., Duriez, Patrick J., Hargreaves, Philip G., Cragg, Mark S., Beers, Stephen A.

“…Following the success of rituximab, 2 other anti-CD20 monoclonal antibodies (mAbs), ofatumumab and obinutuzumab, have entered clinical use. Ofatumumab has…”
Get full text

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation by Beers, Stephen A., Chan, Claude H.T., James, Sonya, French, Ruth R., Attfield, Kathrine E., Brennan, Claire M., Ahuja, Anupama, Shlomchik, Mark J., Cragg, Mark S., Glennie, Martin J.

“…Anti-CD20 monoclonal antibodies (mAbs) are classified into type I (rituximab-like) or type II (tositumomab-like) based on their ability to redistribute CD20…”
Get full text

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking by Turaj, Anna H., Cox, Kerry L., Penfold, Christine A., French, Ruth R., Mockridge, C. Ian, Willoughby, Jane E., Tutt, Alison L., Griffiths, Jordana, Johnson, Peter W. M., Glennie, Martin J., Levy, Ronald, Cragg, Mark S., Lim, Sean H.

“…CD134 (OX40) is a member of the tumour necrosis factor receptor superfamily (TNFRSF). It acts as a costimulatory receptor on T cells, but its role on NK cells…”
Get full text

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells by Cragg, Mark S., Bayne, Mike B., Tutt, Alison L., French, Ruth R., Beers, Stephen, Glennie, Martin J., Illidge, Timothy M.

“…The chimeric anti-CD20 monoclonal antibody (mAb), rituximab, is an established part of the management of many non-Hodgkin lymphomas. The in vivo action of…”
Get full text

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody‐dependent cell‐mediated cytotoxicity and complement‐dependent cytotoxicity by Lohse, Stefan, Loew, Sebastian, Kretschmer, Anna, Jansen, J. H. Marco, Meyer, Saskia, ten Broeke, Toine, Rösner, Thies, Dechant, Michael, Derer, Stefanie, Klausz, Katja, Kellner, Christian, Schwanbeck, Ralf, French, Ruth R., Tipton, Thomas R. W., Cragg, Mark S., Schewe, Denis M., Peipp, Matthias, Leusen, Jeanette H. W., Valerius, Thomas

Get full text